Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer

Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the Phase 2 results.